We are driven to develop innovative and novel medicines to help address unmet medical needs and to elevate life through science.
Our pipeline information may include a reference to an investigational agent or an investigational use of the FDA approved product. Safety and efficacy for investigational uses or agents have not been established or approved by the FDA. This table provides an overview of selected projects in development and can be filtered by both therapeutic area and development phase.
DAYBUE™ (trofinetide) was approved by the U.S. Food and Drug Administration (FDA) in 2023 for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. Click for Important Safety Information.
NUPLAZID ® (pimavanserin) was approved by the FDA in 2016 for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Click for Important Safety Information, including Boxed WARNING.
Results from the Phase 2 ADVANCE study were positive, and a Phase 3 study (ADVANCE 2) is currently being conducted with top-line results anticipated in 2023.
Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases.